US2012207755A1PendingUtilityA1

Cancer

46
Assignee: SELLAR GRANT CLARKPriority: Jun 27, 2001Filed: Feb 17, 2012Published: Aug 16, 2012
Est. expiryJun 27, 2021(expired)· nominal 20-yr term from priority
Inventors:Grant Clark SellarHani Gabra
C12Q 2600/118C12Q 2600/136C12Q 2523/125A61P 35/00C12Q 2600/158C12Q 2600/156C12Q 1/6809C12Q 1/6886C12Q 2600/154
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers.

Claims

exact text as granted — not AI-modified
1 .- 73 . (canceled) 
     
     
         74 . A method of treating cancer in a patient comprising the step of administering to the patient an effective amount of OBCAM polypeptide to ameliorate the cancer. 
     
     
         75 . A pharmaceutical composition comprising OBCAM polypeptide and a pharmaceutically acceptable carrier. 
     
     
         76 . A method according to  claim 74  wherein cancer cells in the patient have mutant or missing OBCAM alleles. 
     
     
         77 . A method according to  claim 74  wherein cancer cells in the patient have a methylated OBCAM gene. 
     
     
         78 . A method according to  claim 74  wherein the patient has a cancer selected from the group consisting of ovarian cancer, colorectal cancer, breast cancer, lung cancer, prostate cancer, cervical cancer, brain cancer and leukaemia. 
     
     
         79 . A method according to  claim 78  wherein the patient has ovarian cancer. 
     
     
         80 . A method according to  claim 74  further comprising administering to the patient an effective amount of another therapeutic anti-cancer agent. 
     
     
         81 . A method according to  claim 74  wherein the patient is a human patient. 
     
     
         82 . A method according to  claim 74  wherein the patient is an animal model of cancer. 
     
     
         83 . A method according to  claim 74  wherein the OBCAM polypeptide is administered intra-peritoneally. 
     
     
         84 . A method according to  claim 74  wherein the OBCAM polypeptide is a functional fusion protein. 
     
     
         85 . A pharmaceutical composition according to  claim 75  wherein the OBCAM polypeptide is a functional fusion protein.

Join the waitlist — get patent alerts

Track US2012207755A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.